NZ748624A - Methods of selecting an individual who will benefit from treatment with a telomerase inhibitor using a formalin fixed paraffin embedded (ffpe) biological sample of solid tumor cancer cells - Google Patents

Methods of selecting an individual who will benefit from treatment with a telomerase inhibitor using a formalin fixed paraffin embedded (ffpe) biological sample of solid tumor cancer cells

Info

Publication number
NZ748624A
NZ748624A NZ748624A NZ74862413A NZ748624A NZ 748624 A NZ748624 A NZ 748624A NZ 748624 A NZ748624 A NZ 748624A NZ 74862413 A NZ74862413 A NZ 74862413A NZ 748624 A NZ748624 A NZ 748624A
Authority
NZ
New Zealand
Prior art keywords
ffpe
treatment
biological sample
cancer cells
benefit
Prior art date
Application number
NZ748624A
Other languages
English (en)
Inventor
Ekaterina Bassett
Bart Burington
Hui Wang
Kevin Eng
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/802,035 external-priority patent/US9200327B2/en
Application filed by Geron Corp filed Critical Geron Corp
Publication of NZ748624A publication Critical patent/NZ748624A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/91245—Nucleotidyltransferases (2.7.7)
    • G01N2333/9125—Nucleotidyltransferases (2.7.7) with a definite EC number (2.7.7.-)
    • G01N2333/9128—RNA-directed DNA polymerases, e.g. RT (2.7.7.49)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
NZ748624A 2012-11-30 2013-11-27 Methods of selecting an individual who will benefit from treatment with a telomerase inhibitor using a formalin fixed paraffin embedded (ffpe) biological sample of solid tumor cancer cells NZ748624A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261732263P 2012-11-30 2012-11-30
US201361780851P 2013-03-13 2013-03-13
US13/802,035 US9200327B2 (en) 2012-11-30 2013-03-13 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US201361798478P 2013-03-15 2013-03-15
US201361809228P 2013-04-05 2013-04-05
NZ708654A NZ708654A (en) 2012-11-30 2013-11-27 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Publications (1)

Publication Number Publication Date
NZ748624A true NZ748624A (en) 2020-08-28

Family

ID=50828470

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ748624A NZ748624A (en) 2012-11-30 2013-11-27 Methods of selecting an individual who will benefit from treatment with a telomerase inhibitor using a formalin fixed paraffin embedded (ffpe) biological sample of solid tumor cancer cells
NZ708654A NZ708654A (en) 2012-11-30 2013-11-27 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ708654A NZ708654A (en) 2012-11-30 2013-11-27 Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors

Country Status (24)

Country Link
EP (4) EP3495495B1 (enExample)
JP (2) JP6359028B2 (enExample)
KR (3) KR102348240B1 (enExample)
CN (2) CN104937110A (enExample)
AU (4) AU2013352105B2 (enExample)
BR (1) BR112015012507B1 (enExample)
CA (1) CA2892445C (enExample)
CY (1) CY1124140T1 (enExample)
DK (2) DK3495495T3 (enExample)
ES (3) ES2972330T3 (enExample)
HR (2) HRP20181991T1 (enExample)
HU (1) HUE054053T2 (enExample)
IL (3) IL282112B (enExample)
LT (2) LT2925889T (enExample)
MX (1) MX362094B (enExample)
NZ (2) NZ748624A (enExample)
PL (2) PL2925889T3 (enExample)
PT (2) PT3495495T (enExample)
RS (1) RS61513B1 (enExample)
SG (1) SG11201504209YA (enExample)
SI (2) SI3495495T1 (enExample)
SM (1) SMT202100142T1 (enExample)
WO (1) WO2014085632A1 (enExample)
ZA (2) ZA201900759B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3029154T (pt) 2008-10-17 2017-12-06 Geron Corp Método para identificação de sensibilidade de um paciente à terapia de inibição da telomerase
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
JPWO2018207952A1 (ja) * 2017-05-12 2020-04-16 国立大学法人九州大学 発毛及び／又は育毛用組成物
TWI879717B (zh) 2017-07-28 2025-04-11 美商傑龍公司 治療骨髓增生不良症候群之方法
EP3829651A4 (en) * 2018-07-31 2022-05-04 Geron Corporation METHODS OF IDENTIFYING PATIENTS WHO WILL BENEFIT FROM TREATMENT WITH A TELOMERASE INHIBITOR
GB201818792D0 (en) * 2018-11-19 2019-01-02 Telonostix Ltd Compounds for telomere length-related treatment of cancer
SG11202105573PA (en) 2018-11-29 2021-06-29 Geron Corp Methods of treating myelodysplastic syndrome
EP3674418A1 (en) * 2018-12-26 2020-07-01 Life Length S.L. Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
CN114306602B (zh) * 2020-09-28 2024-06-11 中国科学院上海营养与健康研究所 靶向tert在调节皮肤及毛发色素中的应用
CN115463122B (zh) * 2022-08-16 2025-03-25 吕梁学院 一种增强盐霉素抗癌活性的方法及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
AU733610B2 (en) 1996-12-20 2001-05-17 Geron Corporation Methods for detecting and inhibiting the RNA component of telomerase
JPH11276182A (ja) * 1997-12-26 1999-10-12 Chugai Pharmaceut Co Ltd 逆転写酵素モチーフを有する新規遺伝子
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
JP4515767B2 (ja) 2002-01-31 2010-08-04 ユニバーシティ・オブ・ユタ 非標的核酸依存性増幅の低減：反復核酸配列の増幅
US20040234961A1 (en) * 2002-04-22 2004-11-25 Fordyce Colleen A. Telomere length determination and applications
EP2474822A1 (en) 2003-01-24 2012-07-11 University of Utah Methods of predicting mortality risk by determining telomere length
JP4690324B2 (ja) 2003-09-09 2011-06-01 ジェロン・コーポレーション テロメラーゼ阻害のための改変オリゴヌクレオチド
RS56361B1 (sr) 2004-07-02 2017-12-29 Geron Corp Sinteza zaštićenih 3'-amino nukleozidnih monomera
JP2008536822A (ja) * 2005-03-25 2008-09-11 アルト ソリューションズ インコーポレーテッド テロメラーゼ陽性細胞におけるテロメア長の調節および癌治療
WO2006113470A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
PT3029154T (pt) * 2008-10-17 2017-12-06 Geron Corp Método para identificação de sensibilidade de um paciente à terapia de inibição da telomerase
CA2748265C (en) 2008-12-22 2018-04-03 University Of Utah Research Foundation Monochrome multiplex quantitative pcr
US20110207128A1 (en) 2010-02-16 2011-08-25 Cawthon Richard M Methods and kits for determining biological age and longevity based on gene expression profiles
WO2012135125A1 (en) 2011-03-28 2012-10-04 Geron Corporation Telomere length measurement in formalin-fixed, paraffin embedded (ffpe) samples by quantitative pcr

Also Published As

Publication number Publication date
ES2865446T3 (es) 2021-10-15
CA2892445C (en) 2022-06-28
IL270636B (en) 2021-04-29
CY1124140T1 (el) 2022-05-27
CN111494629A (zh) 2020-08-07
SI2925889T1 (sl) 2019-01-31
PL2925889T3 (pl) 2019-02-28
KR20150091491A (ko) 2015-08-11
AU2025201333B2 (en) 2025-10-16
ZA202101317B (en) 2023-03-29
KR102348240B1 (ko) 2022-01-10
PL3495495T3 (pl) 2021-08-30
EP3882355B1 (en) 2023-12-20
BR112015012507B1 (pt) 2023-03-07
IL239035A0 (en) 2015-07-30
AU2013352105A1 (en) 2015-06-18
MX362094B (es) 2019-01-07
CA2892445A1 (en) 2014-06-05
EP2925889A1 (en) 2015-10-07
LT2925889T (lt) 2018-12-27
JP2018099127A (ja) 2018-06-28
EP2925889A4 (en) 2016-06-15
BR112015012507A8 (pt) 2019-10-08
HRP20181991T1 (hr) 2019-03-08
EP3495495B1 (en) 2020-12-23
EP3882355C0 (en) 2023-12-20
KR20200128446A (ko) 2020-11-12
WO2014085632A1 (en) 2014-06-05
AU2022202808B2 (en) 2024-11-28
DK2925889T3 (da) 2019-01-02
KR20210112394A (ko) 2021-09-14
ES2972330T3 (es) 2024-06-12
IL282112A (en) 2021-05-31
HK1215874A1 (en) 2016-09-23
DK3495495T3 (da) 2021-03-22
BR112015012507A2 (pt) 2017-07-11
SMT202100142T1 (it) 2021-05-07
IL282112B (en) 2022-09-01
EP3495495A1 (en) 2019-06-12
EP3882355A1 (en) 2021-09-22
JP6359028B2 (ja) 2018-07-18
AU2019283840A1 (en) 2020-01-23
IL239035B (en) 2020-09-30
AU2022202808A1 (en) 2022-05-19
MX2015006538A (es) 2015-09-23
EP2925889B1 (en) 2018-09-05
AU2025201333A1 (en) 2025-03-20
SI3495495T1 (sl) 2021-07-30
HUE054053T2 (hu) 2021-08-30
PT2925889T (pt) 2018-12-12
ES2703914T3 (es) 2019-03-13
RS61513B1 (sr) 2021-03-31
NZ708654A (en) 2020-04-24
CN104937110A (zh) 2015-09-23
LT3495495T (lt) 2021-02-25
SG11201504209YA (en) 2015-06-29
ZA201900759B (en) 2020-10-28
HRP20210451T1 (hr) 2021-05-14
JP2016501523A (ja) 2016-01-21
AU2013352105B2 (en) 2019-09-19
PT3495495T (pt) 2021-03-22
KR102174763B1 (ko) 2020-11-06
EP4497441A2 (en) 2025-01-29

Similar Documents

Publication Publication Date Title
NZ748624A (en) Methods of selecting an individual who will benefit from treatment with a telomerase inhibitor using a formalin fixed paraffin embedded (ffpe) biological sample of solid tumor cancer cells
EP3029155A3 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
EP3236262A3 (en) Surrogate functional diagnostics test for cancer
MX2017014381A (es) Metodos terapeuticos y diagnosticos para cancer.
WO2014144121A3 (en) Classification and actionability indices for lung cancer
NZ723570A (en) Compositions and methods for quantifying a nucleic acid sequence in a sample
WO2011094483A3 (en) Immune gene signatures in cancer
NZ626867A (en) Compositions and methods for the treatment of infections and tumors
MY188938A (en) Therapeutic, diagnostic and prognostic methods for cancer of the bladder
EP4484572A3 (en) Identification and use of circulating nucleic acid tumor markers
MX2014001246A (es) Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
WO2012138783A3 (en) Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
WO2011112845A3 (en) Methods and compositions related to a multi-methylation assay to predict patient outcome
WO2019094780A3 (en) Non-coding rna for detection of cancer
MX2019013309A (es) Animales no humanos deficientes en lncrna.
CA2977439C (en) MICRORNA-BASED METHOD FOR EVALUATING THE PROGNOSIS OF A PATIENT WITH PROSTATE CANCER
MX392040B (es) Estandares de antigeno prostatico y sus usos.
EP2521555A4 (en) METHOD AND COMPOSITIONS FOR INCREASING SENSITIVITY AGAINST TYROSINE KINASE INHIBITORS
WO2012083274A3 (en) Methods for diagnosis, prognosis and methods of treatment
MX2013008252A (es) Firma de pronostico para la recurrencia de cancer colorrectal.
WO2010007083A3 (en) Methods and nucleic acids for analyses of cell proliferative disorders

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2022 BY CPA GLOBAL

Effective date: 20211014

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2023 BY CPA GLOBAL

Effective date: 20221015

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2024 BY CPA GLOBAL

Effective date: 20231012

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241011

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251018